Indian Pharma Faces Challenges Ahead as Patent Cliff Approaches
Indian pharmaceutical companies have diversified their business models, including domestic branded formulations, active pharmaceutical ingredient (API) production, generic exports, contract manufacturing, vaccines, specialty products, and complex generics. As a patent cliff approaches, these companies face a challenging opportunity that requires adapting to new demands to sustain past successes in the evolving pharmaceutical landscape.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (50/100). Lens Score 29/100.
Outlets measured: economictimes, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 1 Sept, 11:09 am. Other outlets followed.
- 1